kirazmattson
1181 posts
Jun 15, 2026
12:35 AM
|
Avanafil (sold under brands such as Avana in some markets) is primarily metabolized in the liver, with the cytochrome P450 enzyme system playing the central role—especially CYP3A4. After oral intake, avanafil is rapidly absorbed and reaches peak plasma levels in about 30–45 minutes. Once in the bloodstream, it undergoes extensive hepatic metabolism. The CYP3A4 enzyme breaks it down into several metabolites, most of which are pharmacologically inactive. This means the therapeutic effect Avana comes from the parent drug, not its breakdown products. Because CYP3A4 is the key pathway, any substance that affects this enzyme can significantly alter avanafil levels. Strong CYP3A4 inhibitors such as ketoconazole, ritonavir, or certain antibiotics can increase avanafil concentration in the blood, raising the risk of side effects like headache, flushing, dizziness, or low blood pressure. Conversely, CYP3A4 inducers may reduce its effectiveness. After metabolism in the liver, the drug and its metabolites are eliminated through both fecal and renal routes, with a larger proportion excreted in the feces. The elimination half-life of avanafil is relatively short—about 5 hours—which is why its action is considered fast-onset but not long-lasting compared to some other PDE5 inhibitors. Overall, avanafil’s metabolism is efficient and predictable in healthy individuals, but it becomes clinically important when liver function is impaired or when interacting medications are involved. This is why dose adjustments or caution are often recommended in patients taking multiple drugs or those with hepatic conditions.
|
